Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

9 Meters Biopharma, Inc. (NMTR)

1.715   -0.055 (-3.11%) 11-25 12:57
Open: 1.8 Pre. Close: 1.77
High: 1.8001 Low: 1.71
Volume: 36,797 Market Cap: 22(M)

Technical analysis

as of: 2022-11-25 1:59:06 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.69     One year: 3.14
Support: Support1: 1.67    Support2: 1.39
Resistance: Resistance1: 2.3    Resistance2: 2.69
Pivot: 2.05
Moving Average: MA(5): 1.8     MA(20): 2.15
MA(100): 4.1     MA(250): 8.93
MACD: MACD(12,26): -0.4     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 8.4     %D(3): 9.9
RSI: RSI(14): 31.3
52-week: High: 21  Low: 0.22
Average Vol(K): 3-Month: 104 (K)  10-Days: 72 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NMTR ] has closed above bottom band by 13.1%. Bollinger Bands are 58.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.81 - 1.82 1.82 - 1.83
Low: 1.72 - 1.74 1.74 - 1.75
Close: 1.75 - 1.77 1.77 - 1.78

Company Description

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Headline News

Thu, 17 Nov 2022
Is 9 Meters Biopharma Inc (NMTR) a Good Buy in the Healthcare Sector? - InvestorsObserver

Mon, 14 Nov 2022
9 Meters Biopharma (NMTR) Announces Continued Immuno-Oncology Collaboration with Gustave Roussy -

Mon, 14 Nov 2022
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy - Yahoo Finance

Wed, 09 Nov 2022
Stocks Lower Wednsday; FTX Fallout Drags Cryptos - InvestorsObserver

Tue, 08 Nov 2022
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress - Business Wire

Tue, 08 Nov 2022
Atara Biotherapeutics, Inc. (ATRA) Q3 2022 Earnings Call Transcript - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 13 (M)
Shares Float 12 (M)
% Held by Insiders 1.2 (%)
% Held by Institutions 18.9 (%)
Shares Short 161 (K)
Shares Short P.Month 207 (K)

Stock Financials

EPS -0.17
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.03
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -51.2
Return on Equity (ttm) -132
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.12
Qtrly Earnings Growth 0
Operating Cash Flow -35 (M)
Levered Free Cash Flow -18 (M)

Stock Valuations

PE Ratio -10.21
PEG Ratio 0
Price to Book value 1.64
Price to Sales 0
Price to Cash Flow -0.63

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.